Staff Profile

Background

Amir

is a based in Translational and Clinical Research

Institute. His major research is in the context of machine learning,

predictive modelling, pattern recognition, feature selection and risk

stratification in big biological datasets.

Amir’s Google scholar profile can be found here

Previous Positions

2016–2021, Blood cancer UK (www.bloodcancer.org.uk ) 

Integrative Biology Fellow, UK

2011–July 2016, Research Associate, UK

2005– 2009, Senior Software Engineer, UK

2003–2004, Software Development Manager, UK

2001–2003, System Analyst and Software Developer, Iran

2000–2003, Software Developer, Iran

Qualifications

2008 – 2012, Newcastle University, UK

PhD in Bioinformatics and Machine Learning. ‘Development of

Artificial Intelligence Systems as a prediction tool in Ovarian cancer’

2007 – 2008, Northumbria University, UK

MSc in Informatics

2004 – 2007, Northumbria University, UK

BSc in Computing Studies

2000-2003, Kerman University, Iran

BSc in computer science

Research funding committees

2023-present, Blood cancer UK-Research Funding Committee

2022-present, Leukaemia UK-Scientific and Medical Advisory Group (SAMAG)

2022-present, UKRI Talent Peer Review College

Awards

2016, Awarded a four years Bloodwise integrative biology

fellowship

2008, EPSRC Research Scholarship for Doctoral Training,

Newcastle University, UK

2008, Best MSc project of the year by British Airways,

Northumbria University, UK

2007, CTA Studentship Scheme, Northumbria University, UK

Student Supervision

MRes: Supervised master’s students between 2009-present

BSc: Supervised undergraduate students (Biomedical Sciences) between 2009-present

Lecturing/Seminars

BMS3025: Bioinformatics, 2008 - present

MMB8007: Cancer studies, 2024 - present

MMB8052 : Bioinformatics for Biomedical Scientists 2021 - present

PGR poster presentation seminar and one-one feedback sessions, 2019 - present

• Articles

  • Enshaei A, Joy M, Butler E, Kirkwood AA, Messina M, Pavoni C, Morgades M, Harrison CJ, Foa R, Ribera J-M, Chiaretti S, Bassan R, Fielding AK, Moorman AV. A robust and validated integrated prognostic index for defining risk groups in adult acute lymphoblastic leukemia: an EWALL collaborative study. Blood Advances 2024, 8(5), 1155-1166.
  • Ostergaard A, Enshaei A, Pieters R, Vora A, Horstmann MA, Escherich G, Johansson B, Heyman M, Schmiegelow K, Hoogerbrugge PM, Den Boer ML, Kuiper RP, Moorman AV, Boer JM, Van Leeuwen FN. The Prognostic Effect of IKZF1 Deletions in ETV6::RUNX1 and High Hyperdiploid Childhood Acute Lymphoblastic Leukemia. HemaSphere 2023, 7(5), e875.
  • Enshaei A, Martinez Elicegui J, Anguiano E, Gibson J, Lawal S, Ampatzidou M, Doubek M, Fielding AK, La Sala E, Middleton E, Rijneveld AW, Turki AT, Zimmermann M, Vora A, Moorman AV. Real-world evaluation of UK high hyperdiploidy profile using a large cohort of patients provided by HARMONY data platform. Leukemia 2023, 37, 2493–2496.
  • Bomken S, Enshaei A, Schwalbe EC, Mikulasova A, Dai Y, Zaka M, Fung K, Bashton M, Lim H, Jones L, Karataraki N, Winterman E, Ashby C, Attarbaschi A, Bertrand Y, Bradtke J, Buldini B, Burke GA, Cazzaniga G, Gohring G, de Groot-Kruseman H, Haferlach C, Lo Nigro L, Parihar M, Plesa A, Seaford E, Sonneveld E, Strehl S, van der Velden V, Rand V, Hunger SP, Harrison CJ, Bacon C, van Delft F, Loh M, Moppett J, Vormoor J, Walker B, Moorman AV, Russell L. Molecular characterisation and clinical outcome of B-cell precursor acute lymphoblastic leukaemia with IG-MYC rearrangement. Haematologica 2023, 108(3), 717-731.
  • Schwab C, Cranston RE, Ryan SL, Butler E, Winterman E, Hawking Z, Bashton M, Enshaei A, Russell LJ, Kingsbury Z, Peden JF, Barretta E, Murray J, Gibson J, Hinchliffe AC, Bain R, Vora A, Bentley DR, Ross MT, Moorman AV, Harrison CJ. Integrative genomic analysis of childhood acute lymphoblastic leukaemia lacking a genetic biomarker in the UKALL2003 clinical trial. Leukemia 2023, 37, 529-538.
  • Sinclair PB, Cranston RE, Raninga P, Cheng J, Hanna R, Hawking Z, Hair S, Ryan SL, Enshaei A, Nakjang S, Rand V, Blair HJ, Moorman AV, Heidenreich O, Harrison CJ. Disruption to the FOXO-PRDM1 axis resulting from deletions of chromosome 6 in acute lymphoblastic leukaemia. Leukemia 2023, 37, 636–649.
  • Moorman AV, Antony G, Wade R, Butler ER, Enshaei A, Harrison CJ, Moppett J, Hough R, Rowntree C, Hancock J, Goulden N, Samarasinghe S, Vora A. Time to Cure for Childhood and Young Adult Acute Lymphoblastic Leukemia Is Independent of Early Risk Factors: Long-Term Follow-Up of the UKALL2003 Trial. Journal of Clinical Oncology 2022, 40(36), 4228-4239.
  • Moorman AV, Barretta E, Butler ER, Ward EJ, Twentyman K, Kirkwood AA, Enshaei A, Schwab C, Creasey T, Leongamornlert D, Papaemmanuil E, Patrick P, Clifton-Hadley L, Patel B, Menne T, McMillan AK, Harrison CJ, Rowntree CJ, Marks DI, Fielding AK. Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study. Leukemia 2022, 36, 625-636.
  • Ciardullo C, Szoltysek K, Zhou P, Pietrowska M, Marczak L, Willmore E, Enshaei A, Walaszczyk A, Ho JY, Rand V, Marshall S, Hall AG, Harrison CJ, Soundararajan M, Eswaran J. Low BACH2 expression predicts adverse outcome in chronic lymphocytic leukaemia. Cancers 2022, 14(1), 23.
  • Newman AM, Zaka M, Zhou P, Blain AE, Erhorn A, Barnard A, Crossland RE, Wilkinson S, Enshaei A, De Zordi J, Harding F, Taj M, Wood KM, Televantou D, Turner SD, Burke GAA, Harrison CJ, Bomken S, Bacon CM, Rand V. Genomic abnormalities of TP53 define distinct risk groups of paediatric B-cell non-Hodgkin lymphoma. Leukemia 2022, 36(3), 781-789.
  • Schwab CJ, Murdy D, Butler E, Enshaei A, Winterman E, Cranston RE, Ryan S, Barretta E, Hawking Z, Murray J, Antony G, Vora A, Moorman AV, Harrison CJ. Genetic characterisation of childhood B-other-acute lymphoblastic leukaemia in UK patients by fluorescence in situ hybridisation and Multiplex Ligation-dependent Probe Amplification. British Journal of Haematology 2022, 196(3), 753-763.
  • Mansur M, Furness CL, Enshaei A, Nakjang S, Alpar D, Colman SM, Minto L, Irving J, Poole BV, Noronha LP, Savola S, Iqbal S, Gribben J, Pombo-de-Oliveira MS, Ford TM, Greaves M, van Delft F. The genomic landscape of teenage and young adult T-cell acute lymphoblastic leukemia. Cancer Medicine 2021, 10(14), 4864-4873.
  • Creasey T, Enshaei A, Nebral K, Schwab C, Watts K, Cuthbert G, Vora A, Moppett J, Harrison CJ, Fielding AD, Haas OA, Moorman AV. Single nucleotide polymorphism (SNP) array-based signature of low hypodiploidy in acute lymphoblastic leukemia. Genes Chromosomes Cancer 2021, 60(9), 604-615.
  • Shi Y, Beckett MC, Blair HJ, Tirtakusuma R, Nakjang S, Enshaei A, Halsey C, Vormoor J, Heidenreich O, Krippner-Heidenreich A, van Delft FW. Phase II-like murine trial identifies synergy between dexamethasone and dasatinib in T-cell acute lymphoblastic leukemia. Haematologica 2021, 106(4), 1056-1066.
  • Naomi M, Boer JM, Enshaei A, Sutton R, Heyman M, Ebert S, Fiocco M, de Groot-Kruseman HA, van der Velden VHJ, Barbany G, Escherich G, Vora A, Trahair T, Dalla-Pozza L, Pieters R, Zur-Stadt U, Schmiegelow K, Moorman AV, Zwaan CM, den Boer M. Minimal Residual Disease, Long-Term Outcome, and IKZF1 Deletions in Down Syndrome Acute Lymphoblastic Leukemia in a Matched Cohort Study. SSRN 2021. Submitted.
  • Michels N, M Boer J, Enshaei A, Sutton R, Heyman M, Ebert S, Fiocco M, Groot-Kruseman HA, van der Velden VHJ, Barbany G, Escherich G, Vora A, Trahair T, Dalla-Pozza L, Pieters R, Stadt U, Schmiegelow K, Moorman AV, Zwaan M, den Boer ML. Minimal residual disease, long-term outcome, and IKZF1 deletions in children and adolescents with Down syndrome and acute lymphocytic leukaemia: a matched cohort study. The Lancet Haematology 2021, 8(10), 700-710.
  • Enshaei A, Vora A, Harrison CJ, Moppett J, Moorman AV. Defining low-risk high hyperdiploidy in patients with paediatric acute lymphoblastic leukaemia: a retrospective analysis of data from the UKALL97/99 and UKALL2003 clinical trials. The Lancet Haematology 2021, 8(11), e828-e839.
  • Bashton M, Hollis R, Ryan S, Schwab CJ, Moppett J, Harrison CJ, Moorman AV, Enshaei A. Concordance of copy number abnormality detection using SNP arrays and Multiplex Ligation-dependent Probe Amplification (MLPA) in acute lymphoblastic leukaemia. Scientific Reports 2020, 10, 45.
  • Enshaei A, O'Connor D, Bartram J, Hancock J, Harrison CJ, Hough R, Samarasinghe S, den Boer ML, Boer JM, de Groot-Kruseman HA, Marquart HV, Noren-Nystrom U, Schmiegelow K, Schwab C, Horstmann MA, Escherich G, Heyman M, Pieters R, Vora A, Moppett J, Moorman AV. A validated novel continuous prognostic index to deliver stratified medicine in pediatric acute lymphoblastic leukemia. Blood 2020, 135(17), 1438-1446.
  • Hamadeh L, Enshaei A, Schwab C, Alonso CN, Attarbaschi A, Barbany G, den Boer ML, Boer JM, Braun M, Dalla Pozza L, Elitzur S, Emerenciano M, Fechina L, Felice MS, Fronkova E, Haltrich I, Heyman MM, Horibe K, Imamura T, Jeison M, Kovács G, Kuiper RP, Mlynarski W, Nebral K, Ivanov Öfverholm I, Pastorczak A, Pieters R, Piko H, Pombo-de-Oliveira MS, Rubio P, Strehl S, Stary J, Sutton R, Trka J, Tsaur G, Venn N, Vora A, Yano M, Harrison CJ, Moorman AV. Validation of the United Kingdom copy-number alteration classifier in 3239 children with B-cell precursor ALL. Blood Advances 2019, 3(2), 148-157.
  • Bartram J, O'connor D, Enshaei A, Moorman A. Combining Genotype Profiling with MRD for More Accurate Prognostication in Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia 2019, 19(Supplement 1), S63-S65.
  • Schwalbe EC, Hicks D, Rafiee G, Bashton M, Gohlke H, Enshaei A, Potluri S, Matthiesen J, Mather M, Taleongpong P, Chaston R, Silmon A, Curtis A, Lindsey JC, Crosier S, Smith AJ, Goschzik T, Doz F, Rutkowski S, Lannering B, Pietsch T, Bailey S, Williamson D, Clifford SC. Minimal methylation classifier (MIMIC): A novel method for derivation and rapid diagnostic detection of disease-associated DNA methylation signatures. Scientific Reports 2017, 7, 13421.
  • Enshaei A, OConnor D, Bartram J, Hancock J, Harrison CJ, Hough R, Samarasinghe S, Schwab C, Vora A, Wade R, Moppett J, Moorman AV, Goulden N. Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia. Journal of Clinical Oncology 2017, 36(1), 34-43.
  • Irving JAE, Enshaei A, Parker CA, Sutton R, Kuiper RP, Erhorn A, Minto L, Venn NC, Law T, Yu J, Schwab C, Davies R, Matheson E, Davies A, Sonneveld E, den Boer ML, Love SB, Harrison CJ, Hoogerbrugge PM, Revesz T, Saha V, Moorman AV. Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukaemia. Blood 2016, 128(7), 911-922.
  • Russell LJ, Jones L, Enshaei A, Tonin S, Ryan SL, Eswaran J, Nakjang S, Papaemmanuil E, Tubio JM, Fielding AK, Vora A, Campbell PJ, Moorman AV, Harrison CJ. Characterisation of the genomic landscape of CRLF2-rearranged acute lymphoblastic leukemia. Genes, Chromosomes & Cancer 2016, 56(5), 363-372.
  • Boer JM, vanderVeer A, Rizopoulos D, Fiocco M, Sonneveld E, deGroot-Kruseman HA, Kuiper RP, Hoogerbrugge P, Horstmann M, Zaliova M, Palmi C, Trka J, Fronkova E, Emerenciano M, Pombo-de-Oliveira MS, Mlynarski W, Szczepanski T, Nebral K, Attarbaschi A, Venn N, Sutton R, Schwab CJ, Enshaei A, Vora A, Stanulla M, Schrappe M, Cazzaniga G, Conter V, Zimmermann M, Moorman AV, Pieters R, denBoer ML. Prognostic value of rare IKZF1 deletion in childhood b-cell precursor acute lymphoblastic leukemia: an international collaborative study. Leukemia 2015, 1-7.
  • Enshaei A, Faith J. Feature Selection with Targeted Projection Pursuit. International Journal of Information Technology and Computer Science 2015, 7(5), 34-39.
  • Gabriel AS, Lafta FM, Schwalbe EC, Nakjang S, Cockell SJ, Iliasova A, Enshaei A, Schwab C, Rand V, Clifford SC, Kinsey SE, Mitchell CD, Vora A, Harrison CJ, Moorman AV, Strathdee G. Epigenetic landscape correlates with genetic subtype but does not predict outcome in childhood acute lymphoblastic leukemia. Epigenetics 2015, 10(8), 717-726.
  • Enshaei A, Robson CN, Edmondson RJ. Artificial Intelligence Systems as Prognostic and Predictive Tools in Ovarian Cancer. Annals of Surgical Oncology 2015.
  • Moorman AV, Enshaei A, Schwab C, Wade R, Chilton L, Elliott A, Richardson S, Hancock J, Kinsey SE, Mitchell CD, Goulden N, Vora A, Harrison CJ. A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic leukemia. Blood 2014, 124(9), 1434-1444.
  • Russell LJ, Enshaei A, Jones L, Erhorn A, Masic D, Bentley H, Laczko KS, Fielding AK, Goldstone AH, Goulden N, Mitchell CD, Wade R, Vora A, Moorman AV, Harrison CJ. IGH@ Translocations Are Prevalent in Teenagers and Young Adults With Acute Lymphoblastic Leukemia and Are Associated With a Poor Outcome. Journal of Clinical Oncology 2014, 32(14), 1453-1462.
  • Marks DI, Moorman AV, Chilton L, Paietta E, Enshaie A, DeWald G, Harrison CJ, Fielding AK, Foroni L, Goldstone AH, Litzow MR, Luger SM, McMillan AK, Racevskis J, Rowe JM, Tallman MS, Wiernik P, Lazarus HM. The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)/MLL-AFF1 prospectively treated in the UKALLXII/ECOG2993 trial. Haematologica 2013, 98(6), 945-952.
  • Marks DI, Moorman AV, Chilton L, Paietta E, Enshaie A, DeWald G, Harrison C, Fielding AK, Foroni L, Goldstone AH, Litzow MR, Luger SM, McMillan AK, Racevskis J, Rowe JM, Tallman MS, Wiernik P, Lazarus HM. The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)/MLL-AFF1 prospectively treated on UKALLXII/ECOG2993. Haematologica 2013, 98(6), 945-952.
  • Enshaei A, Schwab CJ, Konn ZJ, Mitchell CD, Kinsey SE, Wade R, Vora A, Harrison CJ, Moorman AV. Long-term follow-up of ETV6-RUNX1 ALL reveals that NCI risk, rather than secondary genetic abnormalities, is the key risk factor. Leukemia 2013, 27(11), 2256-2259.

• Conference Proceedings (inc. Abstracts)

  • Ampomah I, Burton J, Enshaei A, Al Moubayed N. Generating Textual Explanations for Machine Learning Models Performance: A Table-to-Text Task. In: Proceedings of the 13th Conference on Language Resources and Evaluation (LREC 2022). 2022, Marseille, France: European Language Resources Association (ELRA).
  • Brierley CK, Rodriguez-Meira A, Bashton M, Hamblin A, Fletcher RS, Fox S, Gaskell C, Jackson A, O'Sullivan J, Murphy LC, Sousos N, Enshaei A, Harrison C, Drummond MW, Knapper S, Psaila B, Mead AJ. Molecular Characterisation of Participants in the Phazar Trial Reveals Prognostic Impact of Mutations in Advanced-Phase-MPN. In: 62nd ASH Annual Meeting. 2020, Blood.
  • Creasey T, Enshaei A, Watts K, Cuthbert G, Schwab C, Harrison CJ, Vora A, Fielding AK, Moorman AV. Single Nucleotide Polymorphism Array-Based Signature of Genetic Ploidy Groups in Acute Lymphoblastic Leukemia. In: 61st ASH Annual Meeting. 2019, Orlando, FL, USA: American Society of Hematology.
  • Michels N, Boer JM, Lopez-Yurda M, De Groot-Kruseman HA, van der Velden V, Moorman AV, Enshaei A, Vora A, Sutton R, Trahair T, Dalla-Pozza L, Pieters R, Zwaan MC, Den Boer ML. Minimal Residual Disease and IKZF1 As Predictors of Relapse, and Increased Treatment Related Mortality in Down Syndrome Acute Lymphoblastic Leukemia: A Unique and Large International Matched Case-Control Study. In: 61st ASH Annual Meeting. 2019, Orlando, FL, USA: ASH Publications.
  • Moorman A, Kirkwood A, Enshaei A, Clifton-Hadley L, Lawrie E, Marks D, McMillan A, Menne A, Patrick P, Wrench B, Zuborne-Alapi K, Rowntree C, Fielding A. Clinical Efficacy of a Novel Validated Prognostic Index for Trial Design in Adult Acute Lymphoblastic Leukaemia. In: 24th Congress of the European Hematology Association. 2019, Amsterdam: Lippincott, Williams & Wilkins.
  • Newman AM, Zaka M, Zhou P, Erhorn A, Crossland RE, Wilkinson S, Enshaei A, Taj M, Wood K, Televantou D, Turner SD, Burke A, Harrison CJ, Bomken S, Bacon CM, Rand V. Biallelic inactivation of TP53 is associated with an increased risk of relapse in paediatric B-cell non-Hodgkin lymphoma (B-NHL). In: Sixth International Symposium on Childhood, Adolescent and Young Adult Non‐Hodgkin Lymphoma. 2018, Rotterdam, Netherlands: British Journal of Haematology.
  • Zhou P, Enshaei A, Newman AM, Chagaluka G, Lampert I, Van Noorden S, Erhorn A, Barnard A, Crossland RE, Wilkinson S, Nakang S, Moorman AV, Wood K, Televantou D, Carey P, Bomken S, Bacon CM, Bailey S, Molyneux E, Rand V. A Genomic Classification Model Enables Risk Stratification of Paediatric Endemic Burkitt Lymphona in Malawi. In: Abstracts from the 50th Congress of the International Society of Paediatric Oncology (SIOP). 2018, Kyoto, Japan: Pediatric Blood and Cancer.
  • Zhou P, Enshaei A, Newman AM, Banda K, Chagaluka G, Lampert I, Van Noorden S, Erhorn A, Barnard A, Crossland RE, Wilkinson S, Nakjang S, Moorman AV, Wood K, Televantou D, Carey P, Bomken S, Bacon CM, Bailey S, Molyneux E, Rand V. A genomic classification model enables risk stratification of paediatric endemic Burkitt lymphoma. In: Sixth International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma. 2018, Rotterdam, Netherlands: British Journal of Haematology.
  • Schwab C, Enshaei A, Roberts KG, Russell LJ, Harvey RC, Chen IM, Willman CL, Mullighan C, Vora AJ, Moorman AV, Harrison CH. The Frequency and Outcome of Ph-like ALL Associated Abnormalities in Childhood Acute Lymphoblastic Leukaemia Treated on MRC UKALL2003. In: American Society of Hematology (ASH). 2016, San Diego, CA, USA: American Society of Hematology.
  • Schwalbe E, Hicks D, Rafiee G, Bashton M, Gohlke H, Enshaei A, Potluri S, Matthiesen J, Mather M, Taleongpong P, Chaston R, Crosier S, Smith A, Williamson D, Bailey S, Clifford S. Routine molecular subgrouping of medulloblastoma: Bridging the divide between research and the clinic using low-cost, mass spectrometry-based DNA methylomics. In: 41st ESMO Congress (ESMO 2016). 2016, Copenhagen, Denmark: Oxford University Press.
  • Schwalbe E, Hicks D, Rafiee G, Bashton M, Gohlke H, Enshaei A, Potluri S, Matthiesen J, Mather M, Taleongpong P, Chaston R, Crosier S, Smith A, Bordeaut F, Doz F, Rutkowski S, Lannering B, Bailey S, Pietsch T, Williamson D, Clifford S. Routine Diagnostic Medulloblastoma Subgrouping Using Low-Cost, Low-Input DNA Methylomics: Application to Trials Cohorts Previously Refractory-to-Analysis. In: 17th International Symposium on Pediatric Neuro-Oncology (ISPNO). 2016, Liverpool, UK: Oxford University Press.
  • Moorman AV, Enshaei A, O'Connor D, Bartram J, Hancock J, Harrison CH, Samarasinghe S, Moppett J, Vora AJ, Goulden N. Integrating Genetic Risk Factors with Age, Presenting White Cell Count and MRD Response As Continuous Variables to Predict Relapse in Paediatric Acute Lymphoblastic Leukemia (ALL). In: 58th American Society of Hematology (ASH) Annual Meeting. 2016, San Diego, CA, USA: American Society of Hematology.
  • Ciardullo C, Willmore E, Enshaei A, Zhou P, Rand V, Soundararajan M, Hall A, Harrison C, Eswaran J. BACH2 and BCL6 Cooperatively Fuction as Tumour Suppressors in CLL. In: 21st Congress of the European Hematology Association. 2016, Copenhagen, Denmark: Ferrata Storti Foundation.
  • Enshaei A, Schwab C, Chilton L, Wade R, Hancock J, Mitchell C, Kinsey SE, Goulden N, Vora AJ, Harrison C, Moorman AV. Risk Factor Analysis in Paediatric Acute Lymphoblastic Leukaemia with High Hyperdiploidy. In: 57th American Society of Hematology (ASH) Annual Meeting. 2015, Orlando, FL, USA.
  • Enshaei A, Schwab C, Chilton L, Wade R, Hancock J, Mitchell C, Kinsey SE, Goulden N, Vora AJ, Harrison C, Moorman AV. Risk Factor Analysis in Paediatric Acute Lymphoblastic Leukaemia with High Hyperdiploidy. In: 57th ASH Annual Meeting. 2015, Orlando, USA: American Society of Hematology.
  • Bartram J, O'Connor D, Enshaei A, Moorman AV, Harrison C, Wade R, Clack R, Hancock J, Samarasinghe S, Moppett J, Vora AJ, Goulden N. Long Term Overall Survival of Greater Than 98% in Childhood ALL Patients with Good Risk Features and Low Risk MRD:A Results from a Large Multi-Center Randomized Controlled Trial, UKALL 2003. In: 57th ASH Annual Meeting. 2015, Orlando, USA: American Society of Hematology.
  • Bartram J, O'Connor D, Enshaei A, Moorman AV, Harrison C, Wade R, Clack R, Hancock J, Samarasinghe S, Moppett J, Vora AJ, Goulden N. Long Term Overall Survival of Greater Than 98% in Childhood ALL Patients with Good Risk Features and Low Risk MRD: Results from a Large Multi-Center Randomized Controlled Trial, UKALL 2003. In: 57th American Society of Hematology (ASH) Annual Meeting. 2015, Orlando, FL, USA: American Society of Hematology.
  • O'Connor D, Bartram J, Enshaei A, Moorman AV, Harrison C, Wade R, Clack R, Hancock J, Samarasinghe S, Moppett J, Vora AJ, Goulden N. Integration of Minimal Residual Disease with Other Patient Risk Factors Identifies a Population with Very Poor Overall Survival in Pediatric ALL: Results from the UKALL 2003 Trial. In: 57th American Society of Hematology (ASH) Annual Meeting. 2015, Orlando, FL, USA: American Society of Hematology.
  • Masic D, Enshaei A, Jones L, Harrison C, Russell LJ. Genetic Characterisation of Immunoglobulin Heavy Chain Locus CCAAT Enhancer-Binding Protein Translocated Acute Lymphoblastic Leukaemia. In: 57th American Society of Hematology (ASH) Annual Meeting. 2015, Orlando, FL, USA.
  • Masic D, Enshaei A, Jones L, Harrison C, Russell LJ. Genetic Characterisation of Immunoglobulin Heavy Chain Locus CCAAT Enhancer-Binding Protein Translocated Acute Lymphoblastic Leukaemia. In: 57th ASH Annual Meeting 2015. 2015, Orlando, USA: American Society of Hematology.
  • Moorman AV, Irving J, Enshaei A, Parker CA, Sutton R, Kuiper R, Erhorn A, Minto L, Venn NC, Law T, Yu J, Schwab C, Davies R, Sonneveld E, den Boer ML, Love SB, Harrison CJ, Hoogerbrugge PM, Revesz T, Saha V. Composite Index for Risk Prediction in Relapsed Childhood Acute Lymphoblastic Leukaemia. In: 20th Congress of the European Hematology Association. 2015, Vienna: Ferrata Storti Foundation.
  • Russell LR, Jones L, Enshaei A, Rutherford J, Tonin S, Ryan S, Eswaran J, Papaemmanuil E, Tubio J, Campbell PJ, Moorman AV, Harrison C. Clincial and Genetic Landscapes Differ Between IGH-CRLF2 and P2RY8-CRLF2 Acute Lymphoblastic Leukaemia. In: 57th American Society of Hematology (ASH) Annual Meeting. 2015, Orlando, FL, USA: American Society of Hematology.
  • Russell LJ, Jones L, Enshaei A, Rutherford J, Tonin S, Ryan S, Eswaran J, Papaemmanuil E, Tubio J, Campbell PJ, Moorman AV, Harrison C. Clincial and Genetic Landscapes Differ Between IGH-CRLF2 and P2RY8-CRLF2 Acute Lymphoblastic Leukaemia. In: 57th ASH Annual Meeting 2015. 2015, Orlando, USA: American Society of Hematology.
  • Gabriel AS, Enshaei A, Taylor J, Erhorn A, Schwab C, Rai L, Fielding A, Goulden N, Vora A, Harrison CJ, Moorman AV. Age specific incidence of partner gene and secondary abnormalities in MLL positive acute lymphoblastic leukaemia (ALL). In: 20th Congress of the European Hematology Association. 2015, Vienna, Austria: Ferrata-Storti Foundation/European Hematology Association.
  • Sinclair P, Cheng J, Raninga P, Hanna R, Hollern S, Enshaei A, Blair H, Nakjang S, Ryan S, Eswaran J, Buechler L, Heidenreich O, Harrison C. A Targeted Functional Clone Tracking Assay for the Identification of Tumour Suppressor Genes in BCP- ALL Implicates the Transcription Factors FOXO3 and PRDM1. In: 57th American Society of Hematology (ASH) Annual Meeting. 2015, Orlando, FL, USA: American Society of Hematology.
  • Schwalbe EC, Hicks D, Gohlke H, Rafiee G, Enshaei A, Potluri S, Matthiesen J, Mather M, Chaston R, Crosier S, Smith A, Williamson D, Bailey S, Clifford SC. Routine molecular subgrouping of medulloblastoma: Bridging the divide between research and the clinic using low-cost DNA methylomics. In: 2014 NCRI Cancer Conference. 2014, Liverpool, UK.
  • Lafta F, Rand V, Moorman A, Mitchell C, Kinsey S, Vora A, Cockell S, Schwalbel E, Enshaei A, Strathdee G. Investigation of methylation based biomarkers for prediction of relapse in good prognostic cytogenetic subgroups of childhood acute lymphoblastic leukaemia. In: 10th NCRI Cancer Conference. 2014, Liverpool, UK.
  • Boer J, van der Veer A, Rizopoulos D, Fiocco M, Sonneveld E, HA de Groot-Kruseman, Kuiper RP, Hoogerbrugge PM, Horstmann MA, Zaliova M, Palmi C, Trka J, Fronkova E, Emerenciano M, do Socorro Pombo-de-Oliveira M, Mlynarski W, Szczepanski T, Nebral K, Attarbaschi A, Venn NC, Sutton R, Schwab C, Enshaei A, Vora AJ, Stanulla M, Schrappe M, Cazzaniga G, Conter V, Zimmerman M, Moorman AV, Pieters R, Den Boer ML. 368 Prognostic Value of Rare IKZF1 deletions in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia: An International Collaborative Study. In: 56th ASH Annual Meeting and Exposition. 2014, San Francisco, USA: American Society of Hematology.
  • Moorman AV, Enshaei A, Schwab C, Chilton L, Wade R, Goulden N, Vora AJ, Harrison CJ. Integration Of Cytogenetic and Copy Number Alteration (CNA) Data Into a Single Risk Profile For Paediatric Acute Lymphoblastic Leukaemia (ALL). In: 55th Annual Meeting and Exposition of the American Society of Hematology (ASH). 2013, New Orleans, Louisiana: American Society of Hematology.
  • Russell LJ, Jones L, Erhorn A, Ensahei A, Masic D, Bentley H, Laczko KS, Harrison CJ. Immunoglobulin Heavy Chain Locus (IGH@) Translocations in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL): Incidence and Risk Stratification. In: 54th Annual Meeting and Exposition of the American Society of Hematology (ASH). 2012, Atlanta, Georgia, USA: American Society of Hematology.
  • Moorman AV, Enshaie A, Chilton L, Schwab C, Tembo T, Richards S, Kinsey S, Vora AJ, Mitchell C, Harrison CJ. Delineation of Risk Factors in Paediatric Acute Lymphoblastic Leukaemia with Favourable Cytogenetics. In: 54th Annual Meeting and Exposition of the American Society of Hematology (ASH). 2012, Atlanta, Georgia, USA: American Society of Hematology.
  • Moorman AV, Enshaei A, Chilton L, Schwab C, Tembo T, Richards S, Kinsey S, Vora AJ, Mitchell C, Harrison CJ. Delineation of Risk Factors in Paediatric Acute Lymphoblastic Leukaemia with Favourable Cytogenetics. In: 54th Annual Meeting and Exposition of the American Society of Hematology (ASH). 2012, Atlanta, Georgia, USA: American Society of Hematology.
  • Schwab C, Chilton L, Enshaie A, Morrison H, Jones L, Al-Shehhi HA, Erhorn A, Russell LJ, Vora AJ, Mitchell CD, Richards SM, Goulden N, Kinsey S, Moorman AV, Harrison CJ. Clinical Relevance of Genes Commonly Deleted in Childhood B-Cell Precursor ALL (BCP-ALL). In: 54th Annual Meeting and Exposition of the American Society of Hematology (ASH). 2012, Atlanta, Georgia, USA: American Society of Hematology.

• Letters

  • Moorman AV, Enshaei A, Murdy D, Joy M, Boer JM, den Boer ML, Pieters R, de Haas V, Horstmann MA, Escherich G, Johansson B, Marquart HV, Schmiegelow K, Hancock J, Moppett J, Heyman M. Integration of genetics and MRD to define low risk patients with B-cell precursor acute lymphoblastic leukaemia with intermediate MRD levels at the end of induction. Leukemia 2024, epub ahead of print.
  • Connor DO, Joy M, Enshaei A, Kirkwood A, Kearns PR, Samarasinghe S, Moppett J, Moorman AV, Vora A. Cranial radiotherapy has minimal benefit in children with central nervous system involvement in T-ALL. Blood Advances 2023, 7(23), 7231-7234.

• Working Papers

  • Woodruff N, Enshaei A, Awwad Shiekh Hasan B. Fully-Automatic Pipeline for Document Signature Analysis to Detect Money Laundering Activities. arxiv 2021.
  • McCluskey R, Enshaei A, Awwad Shiekh Hasan B. Finding the Ground-Truth from Multiple Labellers: Why Parameters of the Task Matter. arxiv 2021.